Table 4.
DMARD use during the pre-index period (180 days)
| All (n=1,090) |
SC (n=785) |
IV (n=305) |
P-value IV versus SC |
ETN (n=440) |
ADA (n=345) |
P-value ETN versus ADA |
IFX (n=201) |
P-value ETN versus IFX |
ABA (n=104) |
P-value ETN versus ABA |
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Any DMARD | 72.29 | 81.91 | 47.54 | <0.001 | 80.68 | 83.48 | 0.31 | 52.24 | <0.001 | 38.46 | <0.001 |
| Methotrexate | 58.26 | 66.62 | 36.72 | <0.001 | 65.45 | 68.12 | 0.43 | 44.28 | <0.001 | 66.62 | <0.001 |
| Hydroxychloroquine | 25.96 | 30.57 | 14.1 | <0.001 | 33.18 | 27.25 | 0.07 | 14.43 | <0.001 | 30.57 | <0.001 |
| Leflunomide | 10.83 | 12.61 | 6.23 | 0.002 | 10.91 | 14.78 | 0.10 | 4.98 | 0.02 | 12.61 | 0.50 |
| Sulfasalazine | 10.00 | 11.34 | 6.56 | 0.02 | 11.82 | 10.72 | 0.63 | 6.97 | 0.06 | 11.34 | 0.07 |
Note: Values are presented as percent of patients or P-value.
Abbreviations: ABA, abatacept; ADA, adalimumab; DMARD, disease-modifying antirheumatic drug; ETN, etanercept; IFX, infliximab; IV, intravenous; SC, subcutaneous.